AI Summary
The article discusses the results of a phase 2 trial called ADHERE, which evaluated the safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study found that efgartigimod reduced the risk of relapse compared to placebo in responders to treatment. More research is needed to determine the long-term effects of efgartigimod and compare it to existing treatment options for CIDP.
ADHERE showed the efficacy of subcutaneous efgartigimod PH20 in reducing the risk of relapse versus placebo in people with CIDP who responded to treatment. Further studies are needed to provide data on the longer-term effects of efgartigimod alfa and how it compares with currently available treatment options.